Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Emilia Nunzi, Anna Maria Iorio & Barbara Camilloni. (2017) A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60–85 years old) and very elderly (>85 years old) institutionalized subjects. Human Vaccines & Immunotherapeutics 13:11, pages 2659-2668.
Read now
Read now
Arun Kumar, Janet E. McElhaney, Lisa Walrond, Terry D. Cyr, Shahzma Merani, Tobias R. Kollmann, Scott A. Halperin & David W. Scheifele. (2017) Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison. Human Vaccines & Immunotherapeutics 13:9, pages 2048-2057.
Read now
Read now
Barbara Camilloni, Michela Basileo, Stefano Valente, Emilia Nunzi & Anna Maria Iorio. (2015) Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review. Human Vaccines & Immunotherapeutics 11:3, pages 553-563.
Read now
Read now
Shampur Narayan Madhusudana & Reeta Subramaniam Mani. (2014) Intradermal vaccination for rabies prophylaxis: conceptualization, evolution, present status and future. Expert Review of Vaccines 13:5, pages 641-655.
Read now
Read now
Articles from other publishers (36)
Eamon O Murchu, Laura Comber, Karen Jordan, Sarah Hawkshaw, Liam Marshall, Michelle O’Neill, Máirín Ryan, Conor Teljeur, Annasara Carnahan, Jaime Jesús Pérez, Anna Hayman Robertson, Kari Johansen, Jorgen de Jonge, Tyra Krause, Nathalie Nicolay, Hanna Nohynek, Ioanna Pavlopoulou, Richard Pebody, Pasi Penttinen, Marta Soler‐Soneira, Ole Wichmann & Patricia Harrington. (2022)
Systematic review of the efficacy, effectiveness and safety of MF59
®
adjuvanted seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age
. Reviews in Medical Virology 33:3.
Crossref
Crossref
Francesca L. Mordant, Olivia H. Price, Rajeev Rudraraju, Monica A. Slavin, Caroline Marshall, Leon J. Worth, Heidi Peck, Ian G. Barr, Sheena G. Sullivan & Kanta Subbarao. (2022) Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months. Influenza and Other Respiratory Viruses 17:1.
Crossref
Crossref
Huy Quang Quach & Richard B. Kennedy. (2022) Enhancing Immunogenicity of Influenza Vaccine in the Elderly through Intradermal Vaccination: A Literature Analysis. Viruses 14:11, pages 2438.
Crossref
Crossref
Mahrukh Imran, Joan Puig-Barbera, Justin R Ortiz, Lauren Fischer, Dan O’Brien, Machaon Bonafede, James A Mansi & Constantina Boikos. (2022) Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season. Open Forum Infectious Diseases 9:5.
Crossref
Crossref
Geoffrey J. Gorse, Stephen Grimes, Helen Buck, Hussain Mulla, Peter White, Heather Hill, Jeanine May, Sharon E. Frey & Peter Blackburn. (2022) MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly. Vaccine 40:10, pages 1472-1482.
Crossref
Crossref
Geoffrey J. Gorse, Stephen Grimes, Helen Buck, Hussain Mulla, Peter White, Heather Hill, Jeanine May, Sharon E. Frey & Peter Blackburn. (2022) A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system. Vaccine 40:9, pages 1271-1281.
Crossref
Crossref
Birgit Weinberger. 2022. Healthy Longevity and Immune System. Healthy Longevity and Immune System
119
164
.
Wei Zhan, Todd Hatchette, Fengyun Yue, Jun Liu, Haihan Song, Hanqi Zhao, Stephen Betschel & Mario Ostrowski. (2021) Impaired Memory B-Cell Response to Influenza Immunization in Patients With Common Variable Immunodeficiency (CVID). Pathogens and Immunity 6:2, pages 105-118.
Crossref
Crossref
Constantina Boikos, Lauren Fischer, Dan O’Brien, Joe Vasey, Gregg C Sylvester & James A Mansi. (2021) Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons. Clinical Infectious Diseases 73:5, pages 816-823.
Crossref
Crossref
Janet E. McElhaney & Daniela Frasca. 2021. Encyclopedia of Gerontology and Population Aging. Encyclopedia of Gerontology and Population Aging
2605
2617
.
Janet E. McElhaney, Chris P. Verschoor, Melissa K. Andrew, Laura Haynes, George A. Kuchel & Graham Pawelec. (2020) The immune response to influenza in older humans: beyond immune senescence. Immunity & Ageing 17:1.
Crossref
Crossref
Bahar Behrouzi, Maria Viviana Araujo Campoverde, Kyle Liang, H. Keipp Talbot, Isaac I. Bogoch, Allison McGeer, Ole Fröbert, Mark Loeb, Orly Vardeny, Scott D. Solomon & Jacob A. Udell. (2020) Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19. Journal of the American College of Cardiology 76:15, pages 1777-1794.
Crossref
Crossref
Benjamin J Cowling, Mark G Thompson, Tiffany W Y Ng, Vicky J Fang, Ranawaka A P M Perera, Nancy H L Leung, Yuyun Chen, Hau Chi So, Dennis K M Ip & A Danielle Iuliano. (2020) Comparative Reactogenicity of Enhanced Influenza Vaccines in Older Adults. The Journal of Infectious Diseases 222:8, pages 1383-1391.
Crossref
Crossref
Richard B. Kennedy, Inna G. Ovsyannikova, Peter Palese & Gregory A. Poland. (2020) Current Challenges in Vaccinology. Frontiers in Immunology 11.
Crossref
Crossref
Angelika Wagner & Birgit Weinberger. (2020) Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. Frontiers in Immunology 11.
Crossref
Crossref
Uwe Nicolay, Esther Heijnen, Pantaleo Nacci, Peter A. Patriarca & Brett Leav. (2019) Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. International Journal of Infectious Diseases 85, pages S1-S9.
Crossref
Crossref
Janet E. McElhaney & Daniela Frasca. 2020. Encyclopedia of Gerontology and Population Aging. Encyclopedia of Gerontology and Population Aging
1
12
.
William Schaffner, Paul van Buynder, Shelly McNeil & Albert D. M. E. Osterhaus. (2018) Seasonal influenza immunisation: Strategies for older adults. International Journal of Clinical Practice 72:10, pages e13249.
Crossref
Crossref
Eli B. Nix, Joshua Choi, Christina Anthes, Gabrielle N. Gaultier, Joelle Thorgrimson, Andrew D. Cox, Raymond S. W. Tsang, William G. McCready, Douglas Boreham & Marina Ulanova. (2018) Characterization of natural bactericidal antibody against Haemophilus influenzae type a in Canadian First Nations: A Canadian Immunization Research Network (CIRN) Clinical Trials Network (CTN) study. PLOS ONE 13:8, pages e0201282.
Crossref
Crossref
Marc Baay, Kaatje Bollaerts & Thomas Verstraeten. (2018) A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults. Vaccine 36:29, pages 4207-4214.
Crossref
Crossref
Byung Wook Yoo, Chang Oh KimAllen IzuAshwani Kumar AroraEsther Heijnen. (2018)
Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD
®
and VANTAFLU
®
in South Korean Subjects Aged ≥65 Years
. Infection & Chemotherapy 50:4, pages 301.
Crossref
Crossref
V. Welch, M. Doull, M. Yoganathan, J. Jull, M. Boscoe, S. E. Coen, Z. Marshall, J. Pardo Pardo, A. Pederson, J. Petkovic, L. Puil, L. Quinlan, B. Shea, T. Rader, V. Runnels & S. Tudiver. (2017) Reporting of sex and gender in randomized controlled trials in Canada: a cross-sectional methods study. Research Integrity and Peer Review 2:1.
Crossref
Crossref
Jacqueline U. McDonald, Ziyun Zhong, Helen T. Groves & John S. Tregoning. (2017) Inflammatory responses to influenza vaccination at the extremes of age. Immunology 151:4, pages 451-463.
Crossref
Crossref
Barnaby Young, Xiahong Zhao, Alex R. Cook, Christopher M. Parry, Annelies Wilder-Smith & Mark Chen I-Cheng. (2017) Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine 35:2, pages 212-221.
Crossref
Crossref
Yotam Levin, Efrat Kochba, Georgi Shukarev, Sarah Rusch, Guillermo Herrera-Taracena & Pierre van Damme. (2016) A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine 34:44, pages 5262-5272.
Crossref
Crossref
Brenda L. Coleman, Shelly A. McNeil, Joanne M. Langley, Scott A. Halperin & Allison J. McGeer. (2015) Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. Vaccine 33:48, pages 6635-6640.
Crossref
Crossref
Ryo Arakane, Ryosuke Annaka, Akiko Takahama, Katsuyasu Ishida, Michiharu Yoshiike, Tetsuo Nakayama & Fumihiko Takeshita. (2015) Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study. Vaccine 33:48, pages 6650-6658.
Crossref
Crossref
Claudia Pileggi, Valentina Mascaro, Aida Bianco, Carmelo G. A. Nobile & Maria Pavia. (2015) Immunogenicity and Safety of Intradermal Influenza Vaccine in the Elderly: A Meta-Analysis of Randomized Controlled Trials. Drugs & Aging 32:10, pages 857-869.
Crossref
Crossref
J. Ruiz-Aragón, A.M. Grande Tejada, S. Márquez-Peláez & M. García-Cenoz. (2015) Estimación del impacto de la vacunación antigripal con adyuvante MF59 en población mayor de 64 años para el Sistema Nacional de Salud: efectos y costes. Vacunas 16:1, pages 6-11.
Crossref
Crossref
Barbara Camilloni, Michela Basileo, Angela Di Martino, Isabella Donatelli & Anna Maria Iorio. (2014) Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains. Immunity & Ageing 11:1.
Crossref
Crossref
Robert B Couch, José M Bayas, Covadonga Caso, Innocent Nnadi Mbawuike, Concepción Núñez López, Carine Claeys, Mohamed El Idrissi, Caroline Hervé, Béatrice Laupèze, Lidia Oostvogels & Philippe Moris. (2014) Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infectious Diseases 14:1.
Crossref
Crossref
Sharon E. Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, Nancy Nazaire Bermal, Uwe Nicolay, Vas Narasimhan, Eduardo Forleo-Neto & Ashwani Kumar Arora. (2014) Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 32:39, pages 5027-5034.
Crossref
Crossref
Yu Bin Seo, Won Suk Choi, Jacob Lee, Joon Young Song, Hee Jin Cheong & Woo Joo Kim. (2014) Comparison of the Immunogenicity and Safety of the Conventional Subunit, MF59-Adjuvanted, and Intradermal Influenza Vaccines in the Elderly. Clinical and Vaccine Immunology 21:7, pages 989-996.
Crossref
Crossref
Pierre-Olivier Lang. (2013) Why Influenza Viruses Continue to Pose a Significant Threat to Aging and Aged Populations Worldwide. Current Geriatrics Reports 3:1, pages 56-65.
Crossref
Crossref
Michela Basileo, Anna Maria Iorio, Guido Bartolini, Cinzia Bianchini, Giuseppe Menculini, Paolo Tozzi & Barbara Camilloni. (2014) Comparative Study of Immunogenicity of Split, Intradermal and MF59-adjuvanted Influenza Vaccines in Elderly Institutionalized Subjects. Procedia in Vaccinology 8, pages 18-23.
Crossref
Crossref
Giuseppe Del Giudice & Rino Rappuoli. 2015. Influenza Pathogenesis and Control - Volume II. Influenza Pathogenesis and Control - Volume II
151
180
.